INSMED Inc (INSM) · Aug 6, 2026 · Company update

Brinsupri momentum beats expectations and lifts 2026 guidance sharply

Brinsupri momentum beats expectations and lifts 2026 guidance sharply

The quarter clearly beat the market’s revenue hurdle. Total revenue reached $425.5 million, about 9% above the published consensus of roughly $389.3 million, with the upside concentrated in Brinsupri.

MetricQ2 2026Comparison / expectation
Total revenue$425.5M$107.4M in Q2 2025 (Financial Results)
Brinsupri revenue$309.2M+49% sequentially (Brinsupri Updates)
ARIKAYCE revenue$116.3M+8.3% year over year (ARIKAYCE Updates)
Operating loss$(1.5)M$(312.9)M in Q2 2025 (Financial Results)
2026 Brinsupri revenue guidance$1.25B–$1.4BPreviously greater than $1B (Guidance)
2026 ARIKAYCE revenue guidance$450M–$470MUnchanged; prior range was $450M–$470M (Guidance)

Brinsupri’s launch is tracking ahead, not merely benefiting from a low bar. The company reported roughly 7,000 new patients starting therapy in Q2, more than 6,300 cumulative prescribers, and a 49% sequential revenue increase; it now expects roughly 7,000 new patients per quarter for the rest of 2026. The resulting guidance move to $1.25 billion–$1.4 billion is the filing’s most important change and represents a meaningful upgrade to the commercial outlook (Brinsupri Updates; Guidance).

ARIKAYCE remains a steady asset rather than an incremental upside surprise. Worldwide revenue grew 8.3%, but U.S. revenue rose only 2.2%; the company is relying on potential U.S. and Japanese label expansions for a larger opportunity. Those regulatory filings and preparations are progress, but the 2026 ARIKAYCE guidance was unchanged and excludes any benefit from possible approvals (ARIKAYCE Updates; Guidance).

The pipeline adds support, but not near-term earnings value. The 12-month TPIP open-label data showed improvements in walking distance, biomarkers, functional class, and risk status, while Phase 3 studies remain on schedule. However, the data were presented in July 2026 and are open-label, so this filing mainly reinforces an already-known thesis rather than creating a fresh clinical catalyst (TPIP Updates; Footnotes). The net read is strongly favorable because the Brinsupri beat and guidance increase materially outweigh stable ARIKAYCE performance and continued pipeline execution risk.

Original filing on SEC EDGAR

Brinsupri momentum beats expectations and lifts 2026 guidance sharply | INSM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.